M
Masaya Sugiyama
Researcher at Nagoya City University
Publications - 181
Citations - 6856
Masaya Sugiyama is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 37, co-authored 152 publications receiving 6018 citations.
Papers
More filters
Journal ArticleDOI
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Yasuhito Tanaka,Nao Nishida,Masaya Sugiyama,Masayuki Kurosaki,Kentaro Matsuura,Naoya Sakamoto,Mina Nakagawa,Masaaki Korenaga,Keisuke Hino,Shuhei Hige,Yoshito Ito,Eiji Mita,Eiji Tanaka,Satoshi Mochida,Yoshikazu Murawaki,Masao Honda,Akito Sakai,Yoichi Hiasa,Shuhei Nishiguchi,Asako Koike,Isao Sakaida,Masatoshi Imamura,Kiyoaki Ito,Koji Yano,Naohiko Masaki,Fuminaka Sugauchi,Namiki Izumi,Katsushi Tokunaga,Masashi Mizokami +28 more
TL;DR: A genome-wide association study to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population is reported.
Journal ArticleDOI
Influence of Hepatitis B Virus Genotypes on the Intra- and Extracellular Expression of Viral DNA and Antigens
Masaya Sugiyama,Yasuhito Tanaka,Takanobu Kato,Etsuro Orito,Kiyoaki Ito,Subrat K. Acharya,Robert G. Gish,Anna Kramvis,Takashi Shimada,Namiki Izumi,Masahiko Kaito,Yuzo Miyakawa,Masashi Mizokami +12 more
TL;DR: In this article, the hepatitis B virus (HBV) was transfected with plasmids carrying 1.24-fold the HBV genome of different genotypes/subgenotypes (2 strains each for Aa/A1, Ae/A2, Ba/B2 and D; 3 each for Bj/B1 and C).
Journal ArticleDOI
Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)
Koichi Watashi,Ann Sluder,Takuji Daito,Takuji Daito,Satoko Matsunaga,Akihide Ryo,Shushi Nagamori,Masashi Iwamoto,Syo Nakajima,Senko Tsukuda,Katyna Borroto-Esoda,Masaya Sugiyama,Yasuhito Tanaka,Yoshikatsu Kanai,Hiroyuki Kusuhara,Masashi Mizokami,Takaji Wakita +16 more
TL;DR: It is reported that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes and provides a proof of concept for the novel strategy to identify anti‐HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform.
Journal ArticleDOI
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection.
Atsushi Ozasa,Yasuhito Tanaka,Etsuro Orito,Masaya Sugiyama,Jong-Hon Kang,Shuhei Hige,Tomoyuki Kuramitsu,Kazuyuki Suzuki,Eiji Tanaka,Shunichi Okada,Hajime Tokita,Yasuhiro Asahina,Kazuaki Inoue,Shinichi Kakumu,Takeshi Okanoue,Yoshikazu Murawaki,Keisuke Hino,Morikazu Onji,Hiroshi Yatsuhashi,Hiroshi Sakugawa,Yuzo Miyakawa,Ryuzo Ueda,Masashi Mizokami +22 more
TL;DR: The outcome of acute hepatitis B virus (HBV) infection is variable, influenced by host and viral factors, and fulminant hepatitis was frequent and associated with Bj and lack of HBeAg as well as high replication due to precore mutation in patients with acute HBV infection.
Journal ArticleDOI
An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region
TL;DR: The hepatitis C virus (HCV) genomic database is expanding rapidly and has the potential to provide new insights into the virus’s genetic make-up and evolution.